New Hampshire HB 1809: establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.

Bill Text

HB 1809-FN - AS AMENDED BY THE HOUSE

26Mar2026... 1201h

2026 SESSION

 26-2497

 05/09

HOUSE BILL 1809-FN

AN ACT establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.

SPONSORS: Rep. Scherr, Rock. 26; Rep. C. McGuire, Merr. 27; Rep. Layon, Rock. 13; Rep. Mandelbaum, Rock. 21; Rep. Sabourin dit Choiniere, Rock. 30; Sen. Fenton, Dist 10

COMMITTEE: Health, Human Services and Elderly Affairs

-----------------------------------------------------------------

AMENDED ANALYSIS

 This bill establishes a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 

Explanation: Matter added to current law appears in bold italics.

 Matter removed from current law appears [in brackets and struckthrough.]

 Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

26Mar2026... 1201h 26-2497

 05/09

STATE OF NEW HAMPSHIRE

In the Year of Our Lord Two Thousand Twenty-Six

AN ACT establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.

Be it Enacted by the Senate and House of Representatives in General Court convened:

 1 Statement of Purpose. The medical community has always recognized that patients exist with serious conditions that are very resistant to effective treatment. Recently, research has begun to show that certain of those patients have had positive results with the closely supervised use of psilocybin for treatment. Patients with significant post-traumatic stress disorder, with treatment-resistant clinical depression, and with serious substance use disorder have been shown to benefit from the controlled, therapeutic use of psilocybin in a supervised setting. The purpose of this act is to study the feasibility of the creation of a carefully monitored and closely supervised setting in which an approved medical provider can treat a carefully chosen patient with appropriate doses of psilocybin which that same provider has produced for a medical intervention. 

 2 New Chapter; Medical Psilocybin Advisory Board. Amend RSA by inserting after chapter 126-Z the following new chapter: 

CHAPTER 126-ZZ

Medical Psilocybin Advisory Board

 126-ZZ:1 Definitions. In this chapter: 

 I. “Department” means the department of health and human services. 

 II. “Provider” means an approved medical provider licensed in New Hampshire who has been approved by the department to provide medical services to qualified patients. 

 III. “Producer" means a person who grows and harvests or prepares psilocybin from psilocybin-producing mushrooms, including to compound, convert, process, or manufacture psilocybin products directly or indirectly from psilocybin mushrooms and who has been approved as a provider. 

 IV. “Program” means the medical use of psilocybin program. 

 V. “Psilocybin” means the naturally occurring psychedelic compound 4-phosphoryloxy-N,N-dimethyltryptamine, also known as 4-PO-DMT, and its pharmacologically active metabolite psilocin, 4-hydroxy-N,N-dimethyltryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. 

 VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. 

 VII. “Qualifying condition” means any of the following: 

 (a) Major treatment-resistant depression; 

 (b) Post-traumatic stress disorder; 

 (c) Substance use disorders; and 

 (d) Other conditions recommended by the advisory board to the department. 

 126-ZZ:2 Medical Psilocybin Advisory Board. 

 I. There is hereby established the medical psilocybin advisory board, which shall assess the clinical, quality, and public health related advantages and disadvantages of the use of psilocybin for therapeutic purposes under this chapter and, if appropriate, design a program for the medical use of psilocybin. 

 II. Notwithstanding RSA 14:49, the board shall consist of the following members: 

 (a) The medical director of the department of health and human services, or designee. 

 (b) A qualifying patient, appointed by the commissioner of the department of health and human services. 

 (c) A representative from the veterans’ affairs community, appointed by the commissioner of the department of health and human services. 

 (d) A representative from the house of representatives, appointed by the speaker of the house of representatives. 

 (e) A representative from the house of representatives, nominated by the minority leader of t